Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism

Junzhe CAI; Songbai LIU; Xiaobin FEI; Peng LIU; Changhao ZHU; Xing WANG; Yaozhen PAN

doi:10.12449/JCH240519

Volume 40 Issue 5

May 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(5): 989-996

PDF( 2397 KB)

Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism

DOI: 10.12449/JCH240519

Junzhe CAI¹,
Songbai LIU²,
Xiaobin FEI¹,
Peng LIU³,
Changhao ZHU⁴,
Xing WANG^{1, 4},
Yaozhen PAN^{1, 4
,
,
,}

1.
College of Clinical Medicine，Guizhou Medical University，Guiyang 550000，China
2.
Department of Hepatobiliary Surgery，The Affiliated Baiyun Hospital of Guizhou Medical University，Guiyang 550000，China
3.
Department of Hepatobiliary Surgery，The Affiliated Hospital of Guizhou Medical University，Guiyang 550000，China
4.
Department of Hepatobiliary Surgery，The Affiliated Cancer Hospital of Guizhou Medical University，Guiyang 550000，China

Research funding:

National Natural Science Foundation of China (81960431);

National Natural Science Foundation of China (81960535);

Science and Technology Fund of Guizhou Province (QKHZC［2021］YB444)

More Information

Corresponding author: PAN Yaozhen， panyaozhen@gmc.edu.cn （ORCID： 0000-0002-9300-382X）
Received Date: 2023-10-13
Accepted Date: 2023-11-17
Published Date: 2024-05-25

Abstract

Abstract

Objective To investigate the effect of ankyrin-repeat domain-containing protein 22 （ANKRD22） on the proliferation， invasion， and migration of human hepatoma cells and its molecular mechanism. Methods The TCGA database was used to analyze the expression level of ANKRD22 in normal liver tissue and hepatocellular carcinoma tissue and its association with prognosis. Western Blot and qRT-PCR were used to measure the expression of ANKRD22 in human normal liver cells （L-02） and human hepatoma cells （Huh7， HepG2， MHCC-97H， SK-HEP-1， and SMMC-7721）； CCK-8 assay， EdU， wound healing assay， and Transwell assay were used to observe the effect of ANKRD22 on the proliferation， invasion， and migration of hepatoma cells； Western Blot was used to investigate the association of ANKRD22 with cyclins and EMT-related proteins； KEGG and ssGSEA analyses were performed to investigate the mechanism of action of ANKRD22 in hepatoma cells， and related experiments were conducted for validation. The independent-samples t-test was used for comparison of continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results In the TCGA database， the expression level of ANKRD22 in hepatoma tissue was significantly higher than that in normal liver tissue （t=5.083， P<0.05）， and the patients with a high expression level of ANKRD22 had longer overall survival and disease-related survival than those with a low expression level of ANKRD22 （P<0.05）. The expression level of ANKRD22 in various human hepatoma cell lines was higher than that in human normal liver cells （all P<0.05）. Cell proliferation assay showed that the ANKRD22 overexpression group had significantly higher EdU positive rate and proliferation rate than the Vector group （t=19.60 and 6.72， both P<0.001）， and compared with the si-NC group， the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower EdU positive rate and proliferation rate （all P<0.001）. Compared with the Vector group， the overexpression group had significantly higher expression levels of Cyclin E1， Cyclin D1， CDK7， and CDK4 （t=3.54， 4.95， 6.34， and 5.19， all P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）. The overexpression group had a significantly lower expression level of P27 than the Vector group （t=6.12， P<0.001）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group （both P<0.001）. Invasion and migration experiments showed that compared with the Vector group， the ANKRD22 overexpression group had significantly higher migration rate and number of crossings through the membrane （migration group and invasion group）（t=5.01， 25.60， and 3.67， all P<0.05）， and compared with the si-NC group， thesi-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower migration rate and number of crossings through the membrane （migration group and invasion group）（all P<0.01）. The overexpression group had significantly higher expression levels of N-cadherin， Vimentin， and Snail than the Vector group （t=12.13， 8.85， and 13.97， all P<0.001）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）； the overexpression group had a significantly lower expression level of E-cadherin than the Vector group （t=4.98， P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had a significantly higher expression level than the si-NC group （both P<0.001）. The KEGG enrichment analysis and the ssGSEA analysis showed that ANKRD22 was associated with the PI3K/AKT/mTOR signaling pathway in hepatocellular carcinoma， and the overexpression group had significantly higher expression levels of p-AKT/AKT， p-PI3K/PI3K， and p-mTOR/mTOR than the Vector group （t=12.21， 3.43， and 9.75， all P<0.01）， and the si-ANKRD22#2 group and the si-ANKRD22#3 group had significantly lower expression levels than the si-NC group （all P<0.001）. Conclusion ANKRD22 is highly expressed in hepatoma cells and can promote the proliferation， invasion， and migration of hepatoma cells and the activation of the PI3K/AKT/mTOR signaling pathway.
- Carcinoma， Hepatocellular,
- Ankyrin Repeat,
- Cell Proliferation,
- Cell Movement

FullText(HTML)

References(21)

References

[1]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572-020-00240-3.
[2]	FOGLIA B, TURATO C, CANNITO S. Hepatocellular carcinoma: Latest research in pathogenesis, detection and treatment[J]. Int J Mol Sci, 2023, 24( 15): 12224. DOI: 10.3390/ijms241512224.
[3]	DING CM, HOU JF, TAO GW, et al. Early diagnosis and screening of hepatocellular carcinoma[J/OL]. Chin J Hepatic Surg Electron Ed, 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005. 丁成明, 侯嘉丰, 陶光伟, 等. 肝细胞癌早期诊断和筛查[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005.
[4]	KIM E, VIATOUR P. Hepatocellular carcinoma: Old friends and new tricks[J]. Exp Mol Med, 2020, 52( 12): 1898- 1907. DOI: 10.1038/s12276-020-00527-1.
[5]	LIU XF, ZHANG J, YAO L, et al. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. J Clin Hepatol, 2022, 38( 5): 992- 997. DOI: 10.3969/j.issn.1001-5256.2022.05.004. 刘秀峰, 张珏, 姚琳, 等. 中晚期肝细胞癌靶向联合免疫治疗进展[J]. 临床肝胆病杂志, 2022, 38( 5): 992- 997. DOI: 10.3969/j.issn.1001-5256.2022.05.004.
[6]	YANG SS. Evaluation of Clinical Significance of ANKRD22 in Colorectal Cancer[D]. Hangzhou: Zhejiang University, 2019. DOI: 10.27461/d.cnki.gzjdx.2019.001668. 杨赛赛. ANKRD22在结直肠癌细胞中表达意义的研究[D]. 杭州: 浙江大学, 2019. DOI: 10.27461/d.cnki.gzjdx.2019.001668
[7]	UTSUMI T, HOSOKAWA T, SHICHITA M, et al. ANKRD22 is an N-myristoylated hairpin-like monotopic membrane protein specifically localized to lipid droplets[J]. Sci Rep, 2021, 11( 1): 19233. DOI: 10.1038/s41598-021-98486-8.
[8]	WANG R, WU YH, ZHU Y, et al. ANKRD22 is a novel therapeutic target for gastric mucosal injury[J]. Biomed Pharmacother, 2022, 147: 112649. DOI: 10.1016/j.biopha.2022.112649.
[9]	ZHOU HN, LI YM. Conversion therapy for hepatocellular carcinoma[J/OL]. Chin J Hepatic Surg Electron Ed, 2022, 11( 6): 542- 547. DOI: 10.3877/cma.j.issn.2095-3232.2022.06.002. 周辉年, 李玉民. 肝癌转化治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2022, 11( 6): 542- 547. DOI: 10.3877/cma.j.issn.2095-3232.2022.06.002.
[10]	LU SL, YAO JN, YUAN GD, et al. Current status and prospect of clinical and basic research on conversion therapy for hepatocellular carcinoma[J]. Chin J Exp Surg, 2022, 39( 10): 1837- 1843. DOI: 10.3760/cma.j.cn421213-20220210-01043. 陆世鎏, 姚建妮, 袁观斗, 等. 肝癌转化治疗临床与基础研究现状与展望[J]. 中华实验外科杂志, 2022, 39( 10): 1837- 1843. DOI: 10.3760/cma.j.cn421213-20220210-01043.
[11]	PARRA RG, ESPADA R, VERSTRAETE N, et al. Structural and energetic characterization of the ankyrin repeat protein family[J]. PLoS Comput Biol, 2015, 11( 12): e1004659. DOI: 10.1371/journal.pcbi.1004659.
[12]	LIU X, ZHAO JL, WU Q, et al. ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression[J]. J Neuropathol Exp Neurol, 2023, 82( 7): 631- 640. DOI: 10.1093/jnen/nlad034.
[13]	WU YG, LIU HX, GONG YF, et al. ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression[J]. Bosn J Basic Med Sci, 2021, 21( 3): 294- 304. DOI: 10.17305/bjbms.2020.4701.
[14]	YIN J, FU WF, DAI L, et al. ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1[J]. Sci Rep, 2017, 7( 1): 4430. DOI: 10.1038/s41598-017-04818-y.
[15]	WU YG, CHEN WX, ZHANG B, et al. ANKRD22 knockdown suppresses papillary thyroid cell carcinoma growth and migration and modulates the Wnt/β-catenin signaling pathway[J]. Tissue Cell, 2023, 84: 102193. DOI: 10.1016/j.tice.2023.102193.
[16]	PAN TH, LIU JW, XU S, et al. ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells[J]. Theranostics, 2020, 10( 2): 516- 536. DOI: 10.7150/thno.37472.
[17]	CHEN HH, YANG KQ, PANG LX, et al. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer[J]. J Immunother Cancer, 2023, 11( 2): e005527. DOI: 10.1136/jitc-2022-005527.
[18]	QIU YQ, YANG SS, PAN TH, et al. ANKRD22 is involved in the progression of prostate cancer[J]. Oncol Lett, 2019, 18( 4): 4106- 4113. DOI: 10.3892/ol.2019.10738.
[19]	TIAN LY, SMIT DJ, JÜCKER M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J]. Int J Mol Sci, 2023, 24( 3): 2652. DOI: 10.3390/ijms24032652.
[20]	LI YH, YIN YL, HE Y, et al. SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway[J]. Biochem Biophys Res Commun, 2022, 637: 161- 169. DOI: 10.1016/j.bbrc.2022.11.015.
[21]	CHEN JX, CHEN JD, HUANG JX, et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway[J]. Aging(Albany NY), 2019, 11( 23): 10839- 10860. DOI: 10.18632/aging.102488.

Relative Articles

[1]	Zhiru WANG, Wenjing ZHAO, Xi CHEN. Effect and mechanism of gallic acid on the proliferation， migration， invasion， and apoptosis of human hepatocellular carcinoma HepG2 cells[J]. Journal of Clinical Hepatology, 2025, 41(3): 493-498. doi: 10.12449/JCH250315
[2]	Yanfang HE, Jiaojiao XIE, Lanlan ZHENG, Cai GUO, Yanhua MA. Expression and clinical significance of cell cycle protein-dependent kinase 1 and aurora kinase A in the serum of patients with hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(7): 1390-1396. doi: 10.12449/JCH240717
[3]	Shuyan LIU, Qichang YANG, Yi SHEN, Hong ZHOU, Jinfeng QIAN. Role and prognostic value of matrix metalloproteinase-7 in the migration and immune cell infiltration of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(7): 1420-1427. doi: 10.12449/JCH240721
[4]	Chun CHEN, Kexin WANG, Mengwen HE, Le LI, Chunyan WANG, Yan LIU, Dong JI. Silencing essential meiotic endonuclease 1 inhibits the proliferation of liver cancer cells： A study of related mechanisms[J]. Journal of Clinical Hepatology, 2024, 40(5): 982-988. doi: 10.12449/JCH240518
[5]	Jiannan QIU, Peng WANG, Yin CAO, Zhongxia WANG, Junhua WU, Chunping JIANG. Effect of kinesin family member 15 on the proliferation of hepatocellular carcinoma cells and its mechanism of action[J]. Journal of Clinical Hepatology, 2024, 40(2): 327-334. doi: 10.12449/JCH240217
[6]	Yuyan TANG, Shibin XIE, Jianyun ZHU. Diagnostic efficacy of alpha-fetoprotein and alpha-fetoprotein L3% in hepatitis B virus-related early-stage hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2607-2613. doi: 10.3969/j.issn.1001-5256.2023.11.014
[7]	Changqing WANG, Ling CHEN, Ping XU, Xiaojuan ZHU, Zheng LIU. Expression of miR-409-3p in hepatoma HepG2 cells and its mechanism in cell proliferation[J]. Journal of Clinical Hepatology, 2023, 39(8): 1895-1902. doi: 10.3969/j.issn.1001-5256.2023.08.019
[8]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[9]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[10]	Lu Qian, Cheng Xin, Xia ZhenGuo, Chen Zhong. Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 592-595. doi: 10.3969/j.issn.1001-5256.2020.03.024
[11]	ZHONG FuRui, CHENG HuanLi, ZHANG Hao, DU YiChao, HU QiHui, FU WenGuang, XIA XianMing. Effect of kaempferol on the proliferation,migration,invasion,and apoptosis of human hepatoma Bel-7402 cells[J]. Journal of Clinical Hepatology, 2020, 36(12): 2725-2729. doi: 10.3969/j.issn.1001-5256.2020.12.017
[12]	Zhang Yang, Chen ShuYing, Xu GuangRu. Effect of extracellular ubiquitin on the proliferation,invasion,and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(6): 1289-1292. doi: 10.3969/j.issn.1001-5256.2020.06.020
[13]	Zhu YueKun, Zhao XianQi, Wang DaWei, Zhang Wei, Tian MaoLin, Li ZhengTian, Zhao Long, Li Chao, Jiang HongChi. Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2018, 34(12): 2614-2618. doi: 10.3969/j.issn.1001-5256.2018.12.021
[14]	Li YingYing, Zhan LiFen, Ceng ZheChao, Xu Shen. Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action[J]. Journal of Clinical Hepatology, 2018, 34(4): 784-788. doi: 10.3969/j.issn.1001-5256.2018.04.018
[15]	Sha Liang, He JianBo, Li KeZhi, Chen Chuang, Huang Shan, Zhao YinNong, Lian Fang, Wu GuoBin. Influence of specific down-regulation of LKB1 expression on invasion and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(5): 875-879. doi: 10.3969/j.issn.1001-5256.2017.05.016
[16]	Geng YaJun, Li ShuDong, Liu ShenZheng, Ren JianJun, Zhang Tong. Inhibitory effect of microRNA-149-5p in the proliferation and migration of HepG2 and Bel-7402 hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(6): 1126-1130. doi: 10.3969/j.issn.1001-5256.2017.06.022
[17]	Sun LeiQing, Xu Jing, Chen YongQiang, Zheng Lu, Lu: XiaoTing, Liu JunQuan, Chen FuXing, Zhou ZhongHai. Influence of extracellular signal-regulated kinase 1/2 pathway inhibitor PD98059 on proliferation and killing function of γδT cells cultured in vitro[J]. Journal of Clinical Hepatology, 2016, 32(7): 1388-1391. doi: 10.3969/j.issn.1001-5256.2016.07.038
[18]	Ci DanWangJiu, Chang ZhiHui, Zhao XiangXuan, Lin Kun, Zhang Qiang, Lu ZaiMing, Wang XiaoMing. Effect of continuous irradiation with ~(125)I radioactive seeds in inhibiting HepG2 cell proliferation and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(10): 1920-1924. doi: 10.3969/j.issn.1001-5256.2016.10.019
[19]	Tai BoJun, Yao Min, Gu Xing, Shi Yun, Yu DanDan, Chen Jie, Zheng WenJie, Yao DengFu, Lu ShaoLin. Effects of silencing glypican- 3 gene transcription on proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2013, 29(11): 863-866. doi: 10.3969/j.issn.1001-5256.2013.10.015
[20]	Yang Yang, Yang Liu, Fan HaiNing. Effect of H₂S on intracellular Ca²⁺ concentration in HSCs under H₂O₂^-induced oxidative stress conditions [J]. Journal of Clinical Hepatology, 2012, 28(11): 852-855.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5)

Get Citation

PDF

XML

Article Metrics

Article views (485) PDF downloads(33)

Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism

DOI: 10.12449/JCH240519

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism

DOI: 10.12449/JCH240519

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content